AU2022290257A1 - Proteins that bind cd80 and/or cd86, and ox40l - Google Patents

Proteins that bind cd80 and/or cd86, and ox40l Download PDF

Info

Publication number
AU2022290257A1
AU2022290257A1 AU2022290257A AU2022290257A AU2022290257A1 AU 2022290257 A1 AU2022290257 A1 AU 2022290257A1 AU 2022290257 A AU2022290257 A AU 2022290257A AU 2022290257 A AU2022290257 A AU 2022290257A AU 2022290257 A1 AU2022290257 A1 AU 2022290257A1
Authority
AU
Australia
Prior art keywords
seq
amino acid
acid sequence
chain variable
determining region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022290257A
Other languages
English (en)
Other versions
AU2022290257A9 (en
Inventor
Qi AN
Gang Chen
Alec Gross
Qingyong JI
Yves Fomekong NANFACK
Chia Chi SUN
Bijan ZAKERI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of AU2022290257A1 publication Critical patent/AU2022290257A1/en
Publication of AU2022290257A9 publication Critical patent/AU2022290257A9/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2022290257A 2021-06-08 2022-06-07 Proteins that bind cd80 and/or cd86, and ox40l Pending AU2022290257A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163208478P 2021-06-08 2021-06-08
US63/208,478 2021-06-08
US202263343268P 2022-05-18 2022-05-18
US63/343,268 2022-05-18
PCT/US2022/032482 WO2022261079A2 (en) 2021-06-08 2022-06-07 Proteins that bind cd80 and/or cd86, and ox40l

Publications (2)

Publication Number Publication Date
AU2022290257A1 true AU2022290257A1 (en) 2023-11-30
AU2022290257A9 AU2022290257A9 (en) 2023-12-14

Family

ID=84426420

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022290257A Pending AU2022290257A1 (en) 2021-06-08 2022-06-07 Proteins that bind cd80 and/or cd86, and ox40l

Country Status (11)

Country Link
US (1) US20240262922A1 (cg-RX-API-DMAC10.html)
EP (1) EP4351644A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024524880A (cg-RX-API-DMAC10.html)
KR (1) KR20240019224A (cg-RX-API-DMAC10.html)
AU (1) AU2022290257A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023025553A2 (cg-RX-API-DMAC10.html)
CA (1) CA3218785A1 (cg-RX-API-DMAC10.html)
IL (1) IL309119A (cg-RX-API-DMAC10.html)
MX (1) MX2023014695A (cg-RX-API-DMAC10.html)
TW (1) TW202315890A (cg-RX-API-DMAC10.html)
WO (1) WO2022261079A2 (cg-RX-API-DMAC10.html)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2975057A1 (en) * 2006-07-10 2016-01-20 Fujita Health University Novel anti-cd73 antibody
US9574002B2 (en) * 2011-06-06 2017-02-21 Amgen Inc. Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
US20140370012A1 (en) * 2012-01-27 2014-12-18 Gliknik Inc. Fusion proteins comprising igg2 hinge domains
US9512229B2 (en) * 2015-03-03 2016-12-06 Kymab Limited Synergistic combinations of OX40L antibodies for the treatment of GVHD
WO2016142768A1 (en) * 2015-03-10 2016-09-15 Eureka Therapeutics, Inc. Ror2 antibody
AU2016332900C1 (en) * 2015-09-29 2024-07-04 Amgen Inc. ASGR inhibitors
WO2020192709A1 (en) * 2019-03-27 2020-10-01 Wuxi Biologics (Shanghai) Co., Ltd. Novel bispecific polypeptide complexes

Also Published As

Publication number Publication date
KR20240019224A (ko) 2024-02-14
IL309119A (en) 2024-02-01
EP4351644A2 (en) 2024-04-17
WO2022261079A3 (en) 2023-01-19
MX2023014695A (es) 2024-01-15
CA3218785A1 (en) 2022-12-15
AU2022290257A9 (en) 2023-12-14
JP2024524880A (ja) 2024-07-09
BR112023025553A2 (pt) 2024-02-20
WO2022261079A2 (en) 2022-12-15
US20240262922A1 (en) 2024-08-08
TW202315890A (zh) 2023-04-16
EP4351644A4 (en) 2025-04-30

Similar Documents

Publication Publication Date Title
US20250026850A1 (en) Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
KR102926972B1 (ko) Pd-l1 및 cd137에 결합하는 항체 분자
KR102943539B1 (ko) 인터류킨-2 작용제 및 이의 용도
CN112424229B (zh) 结合cd137和ox40的抗体分子
JP7489316B2 (ja) Pd-li抗原結合部位を有するfc結合断片
JP2022126847A (ja) Tigitに対する抗体
JP2019530434A (ja) アゴニスト活性を有する多価及び多重エピトープ抗体ならびに使用方法
US20240025993A1 (en) Cd19 binding molecules and uses thereof
KR20230008157A (ko) 항체 표적화 clec12a 및 이의 사용
US10988545B2 (en) Anti-GITR antigen-binding proteins and methods of use thereof
KR20230147072A (ko) 인터류킨-2 돌연변이체 및 이의 용도
WO2025054328A1 (en) Bispecific binding construct capable of binding to ackr4, compositions comprising a bispecific binding construct capable of binding to ackr4, and methods of using bispecific binding construct capable of binding to ackr4
US20240262922A1 (en) Proteins that bind cd80 and/or cd86, and ox40l
HK40111520A (en) Proteins that bind cd80 and/or cd86, and ox40l
CN117794575A (zh) 结合cd80和/或cd86,以及ox40l的蛋白质
RU2826084C2 (ru) МОЛЕКУЛЫ АНТИТЕЛА, КОТОРЫЕ СВЯЗЫВАЮТ PD-L1 и CD137
RU2795625C2 (ru) Антигенсвязывающие белки против gitr и способы их применения
JP2024536716A (ja) PD-L1、CD137及び/又はTGFβへの二重特異性及び三重特異性結合タンパク質ならびにそれらの使用
HK40078517B (en) 4-1bb and ox40 binding proteins and related compositions and methods, antibodies against 4-1bb, antibodies against ox40
HK40014601A (en) Anti-gitr antigen-binding proteins and methods of use thereof

Legal Events

Date Code Title Description
SREP Specification republished